593 related articles for article (PubMed ID: 33949775)
1. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.
Chollet B; Guinde J; Laroumagne S; Dutau H; Astoul P
Thorac Cancer; 2021 Jun; 12(11):1752-1756. PubMed ID: 33949775
[TBL] [Abstract][Full Text] [Related]
2. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of the LENT score in patients with malignant pleural mesothelioma.
Söyler Y; Kavurgacı S; Gürel Akan E; Yılmaz Ü
Tuberk Toraks; 2022 Dec; 70(4):341-348. PubMed ID: 36537091
[TBL] [Abstract][Full Text] [Related]
4. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
7. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.
Abisheganaden J; Verma A; Dagaonkar RS; Light RW
Respiration; 2018; 96(4):308-313. PubMed ID: 29945142
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.
Zhang Y; Li R; Gu Y; LiZhu Y; Liu X; Zhang S
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557076
[No Abstract] [Full Text] [Related]
9. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
10. Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.
Klikovits T; Hoda MA; Dong Y; Arns M; Baumgartner B; Errhalt P; Geltner C; Machan B; Pohl W; Hutter J; Eckmayr J; Studnicka M; Flicker M; Cerkl P; Kirchbacher K; Klepetko W
Wien Klin Wochenschr; 2016 Sep; 128(17-18):627-34. PubMed ID: 27457873
[TBL] [Abstract][Full Text] [Related]
11. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
[TBL] [Abstract][Full Text] [Related]
15. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
17. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
20. Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
Kim S; Bull DA; Garland L; Khalpey Z; Stea B; Yi S; Hsu CC
Ann Thorac Surg; 2019 Jan; 107(1):194-201. PubMed ID: 30278171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
